^
Association details:
| Biomarker: | ER Y537S |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | giredestrant (GDC-9545) (Estrogen receptor antagonist, Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
Published date:
07/12/2021
Excerpt:
Here, we disclose our discovery efforts culminating in a clinical candidate, 35 (GDC-9545 or giredestrant)...35 induces tumor regressions either as a single agent or in combination with a CDK4/6 inhibitor in an ESR1Y537S mutant PDX…
Secondary therapy:
CDK4 inhibitor + CDK6 inhibitor
DOI:
10.1021/acs.jmedchem.1c00847
